Implementation of genomic medicine in a health care delivery system: A value proposition?

Authors

  • Joanne E. Wade,

    Search for more papers by this author
    • Joanne E. Wade is Executive Vice President, Strategic Program Development, overseeing the system's major strategic initiatives with a focus on quality, innovation, and market expansion. Ms. Wade oversees the business units of Strategy and Business Development, the research enterprise (Sigfried and Janet Weis Research Center, the Geisinger Center for Health Research and the Center for Clinical Studies) and Geisinger Ventures (a portfolio of entrepreneurial companies).
  • David H. Ledbetter,

    Search for more papers by this author
    • David H. Ledbetter, Ph.D., is Executive Vice President and Chief Scientific Officer at Geisinger Health System. His current research interest includes leveraging the massive amount of genomics data generated during routine patient care for knowledge generation and integration of this information into electronic health records in a clinically useful manner.
  • Marc S. Williams

    Search for more papers by this author
    • Marc S. Williams, M.D., since 2012 Dr. Williams has been director of Geisinger Health System's Genomic Medicine Institute. He has led genomic medicine implementation projects at Geisinger and at his previous institution Intermountain Healthcare. He is a member of the National Human Genome Research Institute's Genomic Medicine Working Group steering committee.

  • * Correspondence to: Marc S. Williams, M.D., Genomic Medicine Institute, Geisinger Health System, 100N Academy Drive Mail Stop 26-20, Danville, PA 17822-2026. E-mail: mswilliams1@geisinger.edu

Abstract

The United States health care system is undergoing significant change and is seeking innovations in care delivery and reimbursement models that will lead to improved value for patients, providers, payers, and employers. Genomic medicine has the potential to be a disruptive innovation that if implemented intelligently can improve value. The article presents the perspective of the leaders of a large integrated healthcare delivery system regarding the decision to invest in implementation of genomic medicine. © 2014 Wiley Periodicals, Inc.

Ancillary